alpha-methyltyrosine methyl ester has been researched along with Idiopathic Parkinson Disease in 2 studies
alpha-methyltyrosine methyl ester: RN given refers to parent cpd
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, A | 1 |
| Pavlova, E | 1 |
| Kolacheva, A | 1 |
| Bogdanov, V | 1 |
| Dilmukhametova, L | 1 |
| Blokhin, V | 1 |
| Valuev, L | 1 |
| Valuev, I | 1 |
| Gorshkova, M | 1 |
| Ugrumov, M | 1 |
| Klockgether, T | 1 |
| Turski, L | 1 |
2 other studies available for alpha-methyltyrosine methyl ester and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Development of early diagnosis of Parkinson's disease on animal models based on the intranasal administration of α-methyl-p-tyrosine methyl ester in a gel system.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Animals; Corpus Striatum; | 2022 |
NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats.
Topics: Animals; Dizocilpine Maleate; Drug Synergism; Electromyography; Levodopa; Male; Methyltyrosines; Mot | 1990 |